Genscript Biotech Reports 2021 Annual Results
Revenue of the Group for the year ended December 31, 2021 was approximately US$511.1 million, representing an increase of 30.8% as compared with approximately US$390.8 million for the year ended December 31, 2020, among which, the external revenue for non-cell therapy business was approximately US$424.7 million, representing an increase of 34.8% as compared with approximately US$315.1 million for...
APA Releases Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)
WASHINGTON, March 19, 2022 /PRNewswire/ -- Today, the American Psychiatric Association (APA) released the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). The manual, which the APA has published and updated since 1952, defines and classifies mental disorders in order to improve diagnosis, treatment and research. Developed with the help of more than 200 subject...
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates
SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced its financial results for the full year ended December 31, 2021 and provided corporate updates on key events and achievements since the start...
Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18th, 2022, Venus Medtech (Hangzhou) Inc. ("Venus Medtech", 2500.HK), a leading provider of integrated solutions for structural heart disease in China, announced the appointment of Shakeel Osman as Senior Vice President of Sales Europe, responsible for the commercialization of congenital heart devices. At present, the company's transcatheter pulmonic valve...
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March...
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
SHANGHAI, March 18, 2022 /PRNewswire/ -- At present, COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants are rampant, resulting in the continuous enhancement of their transmission ability. Amid the repeated waves of COVID-19, in addition to COVID-19 vaccine, the development of effective oral COVID-19 drugs and rapid, simple and innovative testing...
Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China. Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to...
CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China
SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced today that the new drug application (NDA) for pralsetinib for the treatment of rearranged during transfection (RET) fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) has been...
ZEPP HEALTH RANKED TOP FIVE IN GLOBAL SMARTWATCH SHIPMENTS IN 2021
Global sales continued to excel in Brazil, Turkey, Italy, and the Czech Republic in Q4 2021 CUPERTINO, Calif., March 18, 2022 /PRNewswire/ -- Zepp Health (NYSE: ZEPP), a global smart wearable and health technology leader, completed the final quarter of 2021 with yet another season of sharp and steady growth, and achieved a top-five ranking in global adult watch shipments,...
CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment...
SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the global multi-regional phase 3 registrational trial of the anti-PD-1 antibody nofazinlimab (CS1003) in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC), CS1003-305,...
